Hématologie5 articles

Impact 2

Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant

Publié: 2026-12-01

Journal of medical economics

MediLens Indexé: 2026-05-23

This retrospective study assessed the costs and healthcare resource utilization associated with switching from frontline pegaspargase/cal-aspargase pegol to second-line recombinant asparaginase in pediatric and AYA patients with acute lymphoblastic leukemia (ALL). A total of 154 patients were ide...

Lire sur PubMed

Impact 2

Hungry bone syndrome-like state following denosumab in a patient with multiple myeloma.

Publié: 2026-07-01

JCEM case reports

MediLens Indexé: 2026-05-23

This case study presents a 76-year-old man with newly diagnosed multiple myeloma who experienced severe, prolonged hypocalcemia following denosumab treatment. The patient had elevated creatinine and calcium levels prior to treatment, and developed significant mineral imbalances despite aggressive...

Lire sur PubMed

Impact 3

Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.

Publié: 2026-05-22

Hematology/oncology and stem cell therapy

MediLens Indexé: 2026-05-23

Hypophosphatemia is prevalent in patients undergoing CAR-T therapy, occurring in 71.5% of recipients. The condition is linked to an increased risk of immune effector cell-associated neurotoxicity syndrome (ICANS), with a hazard ratio of 2.87. Notably, hypophosphatemia typically precedes ICANS by ...

Lire sur PubMed

Impact 2

Haploidentical donor versus double-unit cord blood transplantation in hematologic malignancies: comparative survival and graft-versus-host disease outcomes from a decade of real-world experience.

Publié: 2026-05-22

BMC cancer

MediLens Indexé: 2026-05-23

This study compares haploidentical donor (HID) and double-unit umbilical cord blood (DUCB) transplantation in 97 patients with hematologic malignancies. HID recipients had faster neutrophil and platelet recovery and lower rates of grade II-IV acute GVHD compared to DUCB recipients. However, overa...

Lire sur PubMed

Impact 2

The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis.

Publié: 2026-05-22

Hematology/oncology and stem cell therapy

MediLens Indexé: 2026-05-23

This study evaluates the outcomes of 32 myelofibrosis patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) using a two-step transplant approach. The approach resulted in favorable 1-year and 5-year overall survival rates of 83% and 68%, respectively, and reduced nonrel...

Lire sur PubMed

Tendances de la Recherche Médicale

Hématologie5 articles

Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant

Hungry bone syndrome-like state following denosumab in a patient with multiple myeloma.

Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.

Haploidentical donor versus double-unit cord blood transplantation in hematologic malignancies: comparative survival and graft-versus-host disease outcomes from a decade of real-world experience.

The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis.

Recevez des résumés quotidiens personnalisés